<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effectiveness of lamotrigine as a monotherapeutic agent for a variety of pediatric <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsies</z:e> was reviewed retrospectively </plain></SENT>
<SENT sid="1" pm="."><plain>Children were categorized as having focal vs <z:e sem="disease" ids="C0014548" disease_type="Disease or Syndrome" abbrv="">generalized epilepsy</z:e> and according to whether they were <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> drug naive or drug exposed </plain></SENT>
<SENT sid="2" pm="."><plain>Data collected included dosages, side effects, length of follow-up, number of prior drugs, and treatment response </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment was considered successful if the patient was <z:hpo ids='HP_0001250'>seizure</z:hpo> free for 6 months or more </plain></SENT>
<SENT sid="4" pm="."><plain>Eighty-three children were identified (average age = 8.7 years); 43 had <z:e sem="disease" ids="C0014547" disease_type="Disease or Syndrome" abbrv="">focal epilepsy</z:e>, 32 had <z:e sem="disease" ids="C0014548" disease_type="Disease or Syndrome" abbrv="">generalized epilepsy</z:e>, and eight were not classified </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-nine patients were classified as having specific syndromes </plain></SENT>
<SENT sid="6" pm="."><plain>Fourteen patients were drug naive </plain></SENT>
<SENT sid="7" pm="."><plain>The median follow-up period was 8 months (mean = 8.5) </plain></SENT>
<SENT sid="8" pm="."><plain>Overall, 45% were <z:hpo ids='HP_0001250'>seizure</z:hpo> free, 44% with <z:e sem="disease" ids="C0014547" disease_type="Disease or Syndrome" abbrv="">focal epilepsy</z:e> and 36% with <z:e sem="disease" ids="C0014548" disease_type="Disease or Syndrome" abbrv="">generalized epilepsy</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> children with <z:e sem="disease" ids="C0270853" disease_type="Disease or Syndrome" abbrv="JME|EJM">juvenile myoclonic epilepsy</z:e> and <z:e sem="disease" ids="C0376532" disease_type="Disease or Syndrome" abbrv="BECTS">benign rolandic epilepsy of childhood</z:e> were <z:hpo ids='HP_0001250'>seizure</z:hpo> free, although not <z:hpo ids='HP_0000001'>all</z:hpo> had been treated for at least 6 months </plain></SENT>
<SENT sid="10" pm="."><plain>One third of drug-naive patients were <z:hpo ids='HP_0001250'>seizure</z:hpo> free </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">Rash</z:e> was the most common side effect and was reported in five patients (6%); two patients discontinued the drug </plain></SENT>
<SENT sid="12" pm="."><plain>None had <z:e sem="disease" ids="C0038325" disease_type="Disease or Syndrome" abbrv="">Stevens-Johnson syndrome</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>One quarter of children experienced nonquantifiable improvements, namely increased alertness and improved behavior regardless of <z:hpo ids='HP_0001250'>seizure</z:hpo> control </plain></SENT>
<SENT sid="14" pm="."><plain>Lamotrigine is effective as a monotherapeutic agent in children for both focal and <z:e sem="disease" ids="C0014548" disease_type="Disease or Syndrome" abbrv="">generalized epilepsies</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>Side effects are relatively uncommon </plain></SENT>
<SENT sid="16" pm="."><plain>Lamotrigine may be an effective firstline agent </plain></SENT>
</text></document>